Giant cell arteritis | |
---|---|
Other names | Temporal arteritis, cranial arteritis,[1] Horton disease,[2] senile arteritis,[1] granulomatous arteritis[1] |
The arteries of the face and scalp | |
Specialty | Rheumatology, emergency medicine, Immunology |
Symptoms | Headache, pain over the temples, flu-like symptoms, double vision, difficulty opening the mouth[3] |
Complications | Blindness, aortic dissection, aortic aneurysm, polymyalgia rheumatica[4] |
Usual onset | Age greater than 50[4] |
Causes | Inflammation of the small blood vessels within the walls of larger arteries[4] |
Diagnostic method | Based on symptoms and blood tests, confirmed by biopsy of the temporal artery[4] |
Differential diagnosis | Takayasu arteritis,[5] stroke, primary amyloidosis[6] |
Treatment | Steroids, bisphosphonates, proton-pump inhibitor[4] |
Prognosis | Life expectancy (typically normal)[4] |
Frequency | ~ 1 in 15,000 people a year (> 50 years old)[2] |
Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels.[4][7] Symptoms may include headache, pain over the temples, flu-like symptoms, double vision, and difficulty opening the mouth.[3] Complications can include blockage of the artery to the eye with resulting blindness, as well as aortic dissection, and aortic aneurysm.[4] GCA is frequently associated with polymyalgia rheumatica.[4]
The cause is unknown.[2] The underlying mechanism involves inflammation of the small blood vessels that supply the walls of larger arteries.[4] This mainly affects arteries around the head and neck, though some in the chest may also be affected.[4][8] Diagnosis is suspected based on symptoms, blood tests, and medical imaging, and confirmed by biopsy of the temporal artery.[4] However, in about 10% of people the temporal artery is normal.[4]
Treatment is typical with high doses of steroids such as prednisone or prednisolone.[4] Once symptoms have resolved, the dose is decreased by about 15% per month.[4] Once a low dose is reached, the taper is slowed further over the subsequent year.[4] Other medications that may be recommended include bisphosphonates to prevent bone loss and a proton-pump inhibitor to prevent stomach problems.[4]
It affects about 1 in 15,000 people over the age of 50 per year.[2] The condition mostly occurs in those over the age of 50, being most common among those in their 70s.[4] Females are more often affected than males.[4] Those of northern European descent are more commonly affected.[5] Life expectancy is typically normal.[4] The first description of the condition occurred in 1890.[1]